Background-Hypertension is associated with impaired glucose metabolism and insulin resistance. Chronic activation of the sympathetic nervous system may contribute to either condition. We investigated the effect of catheter-based renal sympathetic denervation on glucose metabolism and blood pressure control in patients with resistant hypertension. Methods and Results-We enrolled 50 patients with therapy-resistant hypertension. Thirty-seven patients underwent bilateral catheter-based renal denervation, and 13 patients were assigned to a control group. Systolic and diastolic blood pressures, fasting glucose, insulin, C peptide, hemoglobin A 1c , calculated insulin sensitivity (homeostasis model assessment-insulin resistance), and glucose levels during oral glucose tolerance test were measured before and 1 and 3 months after treatment. Mean office blood pressure at baseline was 178/96Ϯ3/2 mm Hg. At 1 and 3 months, office blood pressure was reduced by Ϫ28/Ϫ10 mm Hg (PϽ0.001) and Ϫ32/Ϫ12 mm Hg (PϽ0.001), respectively, in the treatment group, without changes in concurrent antihypertensive treatment. Three months after renal denervation, fasting glucose was reduced from 118Ϯ3.4 to 108Ϯ3.8 mg/dL (Pϭ0.039). Insulin levels were decreased from 20.8Ϯ3.0 to 9.3Ϯ2.5 IU/mL (Pϭ0.006) and C-peptide levels from 5.3Ϯ0.6 to 3.0Ϯ0.9 ng/mL (Pϭ0.002). After 3 months, homeostasis model assessment-insulin resistance decreased from 6.0Ϯ0.9 to 2.4Ϯ0.8 (Pϭ0.001). Additionally, mean 2-hour glucose levels during oral glucose tolerance test were reduced significantly by 27 mg/dL (Pϭ0.012). There were no significant changes in blood pressure or metabolic markers in the control group. Conclusions-Renal denervation improves glucose metabolism and insulin sensitivity in addition to a significantly reducing blood pressure. However, this improvement appeared to be unrelated to changes in drug treatment. This novel procedure may therefore provide protection in patients with resistant hypertension and metabolic disorders at high cardiovascular risk. Clinical Trial Registration-URL: http://www.ClinicalTrials.gov. Unique identifiers: NCT00664638 and NCT00888433.
R enal sympathetic afferent and efferent nerves play an important role in blood pressure regulation. Increased renal sympathetic drive is a common feature in patients with various forms of hypertension, and is associated with components of the metabolic syndrome. [1] [2] [3] There is a bidirectional relationship between sympathetic overactivity inducing insulin resistance and hyperinsulinemia producing sympathetic activation, thus initiating a vicious cycle. 4 A percutaneous, catheter-based approach to reduce renal sympathetic afferent and efferent activity with application of intra-arterial radiofrequency energy has been used successfully to treat drug-resistant hypertension and has been demonstrated to reduce muscle sympathetic nerve activity and renal and total body noradrenaline spillover. [5] [6] [7] Given the involvement of the sympathetic nervous system in metabolic control, it is plausible to speculate that reduction of sympathetic activity by renal denervation may have a substantial effect on glucose metabolism in hypertensive patients. The present study was designed to evaluate the relation between sympathetic activity and glucose metabolism and the role of therapeutic renal denervation in patients with resistant hypertension.
Clinical Perspective on p 1946
Methods This study was approved by the ethic committees at all participating centers in accordance with the Declaration of Helsinki. Patients were treated between March 2009 and May 2010 with subsequent follow-up to 3 months. Systolic, diastolic, and mean arterial blood pressures, as well as fasting glucose, insulin, C peptide, glycosylated hemoglobin (HbA 1c ), and glucose levels during oral glucose tolerance test (OGTT), were measured. All patients gave written informed consent.
Eligible patients were Ͼ18 years of age and had an office blood pressure of Ն160 mm Hg (Ն150 mm Hg for patients with type 2 diabetes mellitus) despite being treated with at least 3 antihypertensive drugs (including 1 diuretic), with no changes in medication for a minimum of 2 weeks before enrollment. Patients were included if they were not pregnant and had a glomerular filtration rate Ն45 mL ⅐ min Ϫ1 ⅐ 1.73 m Ϫ2 (using the Modified Diet in Renal Disease formula). 8 Patients with renal artery anatomy ineligible for treatment (main renal arteries Ͻ4 mm in diameter or Ͻ20 mm in length; hemodynamically or anatomically significant renal artery abnormality or stenosis in either renal artery; a history of prior renal artery intervention, including balloon angioplasty or stenting; multiple main renal arteries in either kidney), type 1 diabetes mellitus, myocardial infarction, unstable angina pectoris, cerebrovascular accident within the last 6 months, or hemodynamically significant valvular disease were excluded from the study. Fifty patients were enrolled; 37 were prospectively assigned to the treatment group following protocols of ongoing therapeutic renal denervation trials (NCT00664638 and NCT00888433), and 13 patients, constituting the control population, were assigned to continued medical therapy and were scheduled for renal denervation in 6 months. Of these, 26 patients (renal denervation, nϭ17; control group, nϭ9) were included in the randomized controlled Symplicity Hypertension-2 trial. 7 In all other patients, the measurements were performed as an extension to the Symplicity protocol (NCT00888433) using the same inclusion and exclusion criteria.
Renal angiograms were performed via femoral access to confirm anatomic eligibility. The treatment catheter (Symplicity and Flex by Ardian Inc, Palo Alto, CA) was introduced into each renal artery by use of a renal double curve or left internal mammary artery guiding catheter. Radiofrequency ablations lasting up to 2 minutes each were applied with low power of 8 W to obtain up to 6 ablations separated (Ͼ5 mm) both longitudinally and rotationally within each renal artery. Treatments were delivered from the first distal main renal artery bifurcation to the ostium. Catheter tip impedance and temperature were constantly monitored, and radiofrequency energy delivery was regulated according to a predetermined algorithm. Patients were given heparin to achieve an activated clotting time of Ͼ250 seconds. Diffuse visceral pain occurred during the radio energy delivery that was managed with intravenous anxiolytics and narcotics. The median procedure time (from initiation to completion of radiofrequency delivery) was 42 minutes.
All patients underwent a complete history and physical examination, assessment of vital signs, review of medication, and blood chemistry (including serum creatinine), as well as assessment of fasting glucose, insulin, C peptide, and HbA 1c at baseline and at each follow-up visit at 1 and 3 months. An OGTT was performed at baseline and after 3 months. The patients were instructed to fast for at least 8 to 12 hours before the OGTT and blood sampling. The OGTT consisted of fasting, 60-, and 120-minute glucose measures. According to the World Health Organization, the results of the OGTT were graded into 4 categories: normal (fasting glucose Ͻ110 mg/dL, 120-minute glucose Ͻ140 mg/dL), impaired fasting glycemia (fasting glucose Ն110 mg/dL, 120-minute glucose Ͻ140 mg/ dL), impaired glucose tolerance (fasting glucose Ͻ126 mg/dL, 120-minute glucose Ն140 mg/dL), and diabetes mellitus (fasting glucose Ն126 mg/dL, 120-minute glucose Ն200 mg/dL). Plasma glucose concentration was assessed with the glucose-oxidase method. Plasma insulin and C-peptide concentrations were measured by a chemiluminescent assay. We determined HbA 1c using a high-performance liquid chromatography method. The glucose values are expressed in milligrams per deciliter, insulin as international microunits per milliliter, C peptide as nanograms per milliliter, and HbA 1c as percent. The insulin sensitivity index was calculated from fasting glucose and insulin values as described: homeostasis model assessment-insulin resistance (HOMA-IR)ϭ(FPGϫFPI)/405, 9 where FPG and FPI are fasting plasma glucose and fasting plasma insulin, respectively. The Quantitative Insulin Sensitivity Check Index (IS QUICKI ) was calculated as follows: IS QUICKI ϭ1/ [log(FPI)ϩlog(FPG)]. 10 Patients were interviewed to determine whether they had taken their complete medication at defined doses. Office blood pressure readings were taken in a seated position after 5 minutes of rest according to the standard Joint National Committee VII guidelines. 11 Averages of the triplicate measures were used. Physicians were instructed not to change medications except when medically required. Patients were instructed to remain adherent to their prescribed drugs and defined doses at each visit.
Statistical Analysis
Baseline data were compared between the renal denervation and control groups with the use of either an independent-samples t test for means or a 2 test for proportions. Changes in fasting glucose and in insulin, C peptide, HbA 1c , HOMA-IR, IS QUICKI , and office blood pressures were analyzed from baseline to 1 and 3 months by 2-factor ANOVA with repeated measures. The Duncan test was used to compute posthoc comparisons of significant values. A 2-tailed value of PϽ0.05 was regarded as statistically significant. Glucose levels during OGTT were analyzed with a paired t test to compare baseline with 3-month results. Simple associations were assessed with the Pearson tests for 2 independent proportions. Data are presented as meanϮSEM. All statistical analyses were performed with SPSS statistical software (version 17.0, SPSS Inc, Chicago, IL).
Results
The treatment (nϭ37) and control (nϭ13) groups were well matched in terms of baseline characteristics, without significant differences between groups ( Table 1) . All patients were maintained on baseline antihypertensive medication and followed up for 3 months. Table 1 shows the demographic indicators and clinical characteristics. Most patients were male (nϭ37, 74%). The mean age was 59.7Ϯ1.4 years. On average, patients were taking 5.6Ϯ0.2 antihypertensive drugs, with 47 (94%) receiving an angiotensin-converting enzyme inhibitor, angiotensin II receptor blocker, or both; 44 (88%) taking ␤-blockers; 36 (72%) taking calcium channel blockers; and 34 (68%) receiving centrally acting sympatholytic agents. All patients received diuretics, with 14 (28%) taking aldosterone antagonists. Patients with type 2 diabetes mellitus (nϭ20, 40%) were diagnosed at least 12 months previously. Diagnosis was confirmed as recommended by the American Diabetes Association. 12 Sixteen patients received antidiabetic drugs: metformin (nϭ15), gliclazide (nϭ5), or combined therapy. None of the patients changed the antidiabetic treatment during follow-up. None of the patients was on insulin treatment. Weight and body mass index were similar at baseline and at 3 months, and were unchanged in both groups.
At baseline, overall mean sitting office systolic blood pressure was 178Ϯ2.7 mm Hg, and mean sitting office diastolic blood pressure was 96Ϯ2.2 mm Hg, with a heart rate of 70.9Ϯ2.1 bpm. Renal denervation significantly reduced systolic (Ϫ28Ϯ2 mm Hg; PϽ0.001) and diastolic (Ϫ10Ϯ2 mm Hg; PϽ0.001) blood pressures at 1 month after the procedure; the reductions persisted to the 3-month follow-up (Ϫ32/Ϫ12Ϯ4/2 mm Hg; PϽ0.001; Figure 1 ). Control patients had a slight, but not significant, change in blood pressure of Ϫ8/Ϫ4 mm Hg (Pϭ0.192/0.154) and Ϫ5/ Ϫ3 mm Hg at 1 and 3 months (Pϭ0.494/0.277), respectively. Three of the treated patients (9%) were nonresponders with a systolic blood pressure reduction of Ͻ10 mm Hg. On average, patients received 5.6 antihypertensive drugs at baseline and were instructed not to change their medications unless adverse effects occurred. There were no changes in medication during the study period in any of the patients up to the 3-month follow-up, when repeated testing was performed. However, after the 3-month follow-up visit, in 13 treated patients, antihypertensive medication had to be reduced owing to hypotension associated with symptoms. Therefore, de-escalation in antihypertensive drug treatment became necessary. In 2 control patients and 1 treatment patient, antihypertensive medication had to be further increased after the development of symptoms or signs considered to be consequences of hypertension. To exclude postprocedural renovascular abnormalities, we performed renal duplex ultrasound at the 3-month follow-up and found no detectable abnormalities of the renal arteries. One patient developed a pseudoaneurysm at the femoral access site that was treated without further sequelae. No other complications were observed.
Three months after denervation, fasting glucose was reduced significantly from 118Ϯ3.4 to 108Ϯ3.8 mg/dL (Pϭ0.039; Figure 2A ); there were no significant changes in the control group. Insulin levels decreased from 20.8Ϯ3.0 to 9.3Ϯ2.5 IU/mL (Pϭ0.006; Figure 2B ), which was associated with a reduction in C-peptide levels from 5.3Ϯ0.6 to 3.0Ϯ0.9 ng/mL (Pϭ0.002; Figure 2C ). At baseline, 13 patients in the treatment group had insulin levels Ն20 IU/mL. Treatment decreased this number by 77% (nϭ10), with no changes in the control group. Changes in fasting glucose and insulin levels did not correlate to office systolic (rϭ0.141, Pϭ0.433 and rϭϪ0.242, Pϭ0.175) or diastolic (rϭ0.05, Pϭ0.806 and rϭϪ0.184, Pϭ0.313) blood pressure reduction. Insulin sensitivity, measured with HOMA-IR and IS QUICKI , increased significantly after renal denervation (Figure 2D) . The HOMA-IR decreased from 6.0Ϯ0.9 to 2.4Ϯ0.8 (Pϭ0.001), and the IS QUICKI increased from 0.32Ϯ0.01 to 0.36Ϯ0.01 (Pϭ0.001). Even in the subgroup of patients (nϭ13) with diagnosed diabetes mellitus at study entry, renal denervation significantly reduced fasting glucose, insulin, and C-peptide levels and improved insulin sensitivity after 3 months. The HbA 1c levels remained nearly at baseline values (5.7Ϯ0.1%) and did not change significantly during 3 months of follow-up. Mean reductions in glucose levels during OGTT after 3 months were Ϫ9Ϯ12.0 mg/dL (Pϭ0.510) at 60 minutes and Ϫ27Ϯ10.1 mg/dL (Pϭ0.012) at 120 minutes in the treatment group but not in the control group. In 34 patients (treatment group, nϭ25; control group, nϭ9), the OGTT at baseline revealed 8 patients with impaired fasting glycemia, 18 patients with impaired glucose tolerance, and 8 patients with diabetes mellitus. After the procedure, 7 of 25 patients showed improvement in OGTT. Impaired fasting glycemia, impaired glucose tolerance, or both improved in 16% (nϭ4); the number of patients diagnosed with diabetes mellitus on the basis of OGTT was reduced by 12% (nϭ3); and the number of patients with normal glucose tolerance increased by 16% (nϭ4). Patients in the control group had no significant changes in glucose or insulin metabolism during follow-up, despite an increase in impaired fasting glycemia, impaired glucose tolerance, or both by 1 and an increase in diabetes mellitus by 2 (Table 2 and Figure 3 ).
Discussion
The data identify the renal sympathetic nervous system as an important regulator of insulin resistance and show that renal nerve ablation substantially improves insulin sensitivity and glucose metabolism, in addition to significantly reducing blood pressure. Percutaneous renal denervation may represent the first nonpharmaceutical approach for treating insulin resistance and drug-resistant hypertension.
Activation of the sympathetic nervous systems contributes to insulin resistance 13 and the metabolic syndrome 14 and is associated with central obesity 15 and risk of developing diabetes mellitus. 3 Although insulin itself exhibits sympathoexcitatory effects, 16, 17 renal denervation allows examination of the direct role of the sympathetic nervous system, without causing further systemic pharmacological interactions, in mediating insulin resistance and its consequences. Inhibition of the sympathetic nervous system by moxonidine has been shown to improve glucose metabolism by decreasing glucagon secretion and increasing skeletal blood flow with less glycogenolysis and gluconeogenesis, 18 which is in favor of the pathophysiological relation between the central nervous system and insulin resistance. 19 However, the use of centrally acting sympatholytics is nonspecific and limited by adverse effects, leading to high nonadherence rates. 20 Elevated fasting glucose levels, impaired glucose tolerance, and diabetes mellitus have been associated with an increased risk of cardiovascular disease [21] [22] [23] [24] resulting from stimulation of inflammation, oxidative stress, and thrombotic activity, 25 as well as inhibition of vascular smooth muscle cell apoptosis. 26 Approximately 50% of patients with essential hypertension are considered to be insulin resistant. 27 Insulin resistance is involved in type 2 diabetes mellitus, with a progression from impaired fasting glycemia to impaired glucose tolerance and to overt diabetes mellitus. Renal denervation may reduce the progression from insulin resistance to frank diabetes mellitus, or, in some cases, may reverse underlying diabetes mellitus. Compared with the Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE) trial, 28 which examined the impact of 2 hypoglycemic agents and failed to show significant changes in insulin resistance, as measured by HOMA-IR, therapeutic renal denervation substantially reduces insulin and glucose levels and calculated insulin resistance. A clinical strategy of significantly reducing central sympathetic tone may simultaneously reduce the 2 leading cardiovascular risk factors in hypertensive patients: blood pressure and diabetic status.
The blood pressure reductions shown here are in line with the findings of a proof-of-concept study and the recently published results of the randomized controlled trial. Catheterbased renal denervation resulted in impressive office-based blood pressure reductions of Ϫ32/Ϫ12 mm Hg (PϽ0.0001) after 6 months compared with the control group 7 without affecting other pelvic, abdominal, or lower-extremity innervation and with no evidence of late renovascular complications within 24 months. 5, 7, 29 Effective denervation of the efferent renal sympathetic fibers was shown in 10 patients by measurement of renal noradrenaline spillover, which was reduced by 47% after treatment. 5 Renal denervation also reduced central sympathetic outflow, measured by muscle sympathetic nerve activity, indicating an alteration in afferent sympathetic drive. 6 The substantial improvement in insulin sensitivity and glucose metabolism in response to renal denervation may be explained by a combination of beneficial effects of sympathoinhibition, reduced release of noradrenaline on regional hemodynamics, and direct cellular effects. 15,30 -32 There is evidence that the increase in forearm noradrenaline release accompanied by reduced blood flow is associated with a markedly reduced glucose uptake, indicating an impaired ability of the cell to transport glucose across its membrane. 31 This is related to the neurally mediated reduction in the number of open capillaries, resulting in an increased distance that insulin must travel to reach the cell membrane from the intravascular compartment. 32 This situation is further aggravated by the fact that the insulin-mediated increase in muscle perfusion is reduced by Ϸ30% in insulinresistant states. 30 The relevance of these hemodynamic consequences of sympathetic activation is highlighted by studies demonstrating a direct relationship between muscle sympathetic nerve activity and insulin resistance, and by an inverse relationship between insulin resistance and the number of open capillaries. 15 The findings of our study using a novel interventional approach to substantially reduce sympathetic nerve activity in humans provide further persuasive evidence for a significant role of the sympathetic nervous system as a regulator of insulin sensitivity and glucose metabolism.
Our study has some potential limitations, including potential interference with drug effects. However, there were no changes in medication in the first 3 months, when testing occurred. A decrease in antihypertensive drugs that have been shown to influence insulin sensitivity (eg, ␤-blockers, diuretics, angiotensin-converting enzyme inhibitors) 33 could have had an impact on our results. Despite the fact that patients and physicians were instructed not to change medication during the study period, it is possible that patients changed it themselves. Adherence to the prescribed drug regimen was an inclusion criterion of the study and was checked before study entrance and at each visit, making a self-reduction of drug treatment unlikely. During the normal 120-day lifespan of the red blood cell, glucose molecules react with hemoglobin, forming glycohemoglobin (HbA 1c ) and indicating long-term serum glucose regulation. All patients, particularly those with diabetes mellitus, were adequately controlled with their antidiabetic treatment (mean HbA 1c , 6.0%). Therefore, it is not surprising that no significant changes in HbA 1c levels during follow-up of 3 months were detected, whereas insulin, C peptide, fasting glucose, and insulin sensitivity were significantly changed by renal denervation. Insulin sensitivity was calculated with the use of 2 different equations (HOMA-IR and IS QUICKI ). 9, 10 Both parameters correlate to the results of hyperinsulinemic-euglycemic clamp and are associated with sympathetic activity, measured by muscle sympathetic nerve activity. 15 However, the gold standard for assessment of insulin sensitivity is the hyperinsulinemic-euglycemic clamp method, which was not performed here. An intervention that dramatically reduces blood pressure, as shown here, might lead to changed health behaviors in some individuals. Although body mass index was not significantly changed after renal denervation, a positive interference by increased physical activity or changed dietary habits might have influenced glucose metabolism. The possibility that a reduction in blood pressure itself accounts for the observed improvements in glucose metabolism and insulin resistance cannot be excluded. However, similar changes in insulin resistance have not been reported for direct and nonspecific vasodilators, 34 whereas smaller changes in insulin resistance have been reported for some nonspecific ␤-blockers 33 and central sympatholytics. 18 Direct assessment of sympathetic activity was not part of the study protocol, although renal denervation has been shown to reduce renal sympathetic afferent and efferent activity, as measured by noradrenaline spillover and muscle sympathetic nerve activity. 5, 6 Available data with 24 months of follow-up indicate that renal denervation offers a new and safe approach for the treatment of resistant hypertension. 29 However, continuous follow-up is necessary to exclude long-term adverse effects after renal denervation.
Conclusions
Renal denervation offers a novel and safe catheter-based approach for selective reduction of renal sympathetic drive. We demonstrated for the first time that selective denervation of the renal sympathetic nerves has the potential to improve glucose metabolism and blood pressure control concurrently in patients with resistant hypertension in the absence of significant changes in body weight and alterations in lifestyle or antihypertensive medication. However, the possibility that the blood pressure reduction itself or any change in antihypertensive drug treatment not captured by the study protocol accounts for the observed improvements in glucose metabolism and insulin resistance is unlikely but cannot be completely excluded. These data add significantly to the concept that sympathetic activation underlies the origin of linked disorders of hypertension and metabolic syndrome, and raise hopes that both important features of cardiovascular risk can be addressed simultaneously.
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